I’ve been stuck on a recurring pattern in my longitudinal models: the age-related decline in GLP-1 isn't just a matter of output. We see a clear dip in postprandial secretion from enteroendocrine L-cells, but the systemic response stays fundamentally blunted, even when we supplement with exogenous agonists.

This brings me to two competing hypotheses that I keep revisiting. Are we dealing with L-cell secretory exhaustion, or is it a case of downstream receptor desensitization?

If it's secretory exhaustion, we’re looking at an intrinsic, age-driven failure of the sensing apparatus—likely linked to mitochondrial dysfunction or shifts in GPCR signaling sensitivity within the duodenal epithelium. If that’s the primary driver, then interventions ought to focus on boosting local metabolic flux or cleaning up the mucosal environment.

However, if it’s receptor desensitization—a systemic downregulation of GLP-1R expression or trafficking efficiency—then the gut is just a bystander, affected by chronic inflammation or dysregulated insulin signaling crosstalk. In that case, pushing the ‘brake’ harder via agonists might be counterproductive, potentially worsening the homeostatic resistance.

I’m leaning toward the latter; I suspect the duodenum acts as a sensor of systemic noise rather than the primary site of failure. Still, the data on L-cell density turnover vs. receptor density across the human lifespan is frustratingly thin.

I’d like to hear from those working on gut-brain axis kinetics:

1. Do we see parallel receptor downregulation in the nucleus tractus solitarius (NTS) as we do in the periphery?
2. Is the decline in GLP-1 potency driven by proprotein convertase subtilisin/kexin (PCSK) shifts?
3. Could we tease these mechanisms apart using a short-term, low-dose agonist challenge paired with isotope-labeled nutrient sensing?

My hunch is that the bottleneck is an integration error, not a supply issue. Let's dig into it.